Cardiovascular risks increased with use of inhaled long-acting bronchodilators
KEY POINT
New use of long-acting beta-2 agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in patients with chronic obstructive pulmonary disease (COPD) was associated with a 1.5-fold increased risk of cardiovascular (CV) events within 30 days of treatment initiation, according to a nested case-control study in JAMA Internal Medicine.
SOURCES
Wang MT, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: A nested case-control study. JAMA Intern Med. 2018;[Epub ahead of print].
Maris NA, et al. Anti-inflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med. 2005;172(7):878–84.
Toumpanakis D, et al. Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, and experimental model of severe airway obstruction. Int J Chron Obstruct Pulomn Dis. 2017;12:2207–20.
Wise RA, et al. Tiotropium Respimat inhaler in COPD and risk of death. N Engl J Med. 2013;369(16):1491–1501.
